pe Application of Biomaterials in pe Treatment of Platinum-Resistant Ovarian Cancer

摘要

More pan 70%ofwomenwip ovarian cancerare diagnosed wip advanced-stage disease, which is initially treated wip cy- toreductive surgery,and combination chemoperapy wip plati- num-based compounds. Most patients initially respond to plat- inum-based perapy,but eventually up to 80%ofpis respon- sive cohortbecomes refractory due to pe development of platinum resistance. pis review discusses current and poten- tial perapeutic approaches pat exploit biomaterial-based ap- plicationstocombat platinum resistance eiper by enhancing pe delivery of platinum-based drugs or prodrugs, delivering oper toxic non-platinum-based bioactive factors (by pem- selves or in combination wip platinum-based drugs) or by de- livering oper bioactive factorspat re-sensitize resistant ovari- an cancer cells to pese drugs. pe types of materials pat are used, pe bioactive factors applied (i.e. ,drug or gene delivery), and pe specific agents pat are employed to target pese types of cancercells are discussed. We conclude pat pe unique attributes of biomaterial-based applications can be fur- per explored towardovercoming platinum-resistant ovarian cancer as monoperapy,orincombination wip oper treat- ment strategies.